Compare FMBH & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMBH | MNMD |
|---|---|---|
| Founded | 1865 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 974.1M | 960.2M |
| IPO Year | N/A | N/A |
| Metric | FMBH | MNMD |
|---|---|---|
| Price | $41.98 | $12.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $43.20 | $25.78 |
| AVG Volume (30 Days) | 73.8K | ★ 1.5M |
| Earning Date | 01-22-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.38% | N/A |
| EPS Growth | ★ 12.54 | N/A |
| EPS | ★ 3.65 | N/A |
| Revenue | ★ $335,099,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $19.36 | N/A |
| P/E Ratio | $11.49 | ★ N/A |
| Revenue Growth | ★ 5.91 | N/A |
| 52 Week Low | $27.58 | $4.70 |
| 52 Week High | $42.50 | $14.43 |
| Indicator | FMBH | MNMD |
|---|---|---|
| Relative Strength Index (RSI) | 74.21 | 51.78 |
| Support Level | $39.70 | $12.19 |
| Resistance Level | $42.50 | $13.02 |
| Average True Range (ATR) | 0.85 | 0.65 |
| MACD | 0.34 | 0.04 |
| Stochastic Oscillator | 88.70 | 36.74 |
First Mid Bancshares Inc is a United States based financial holding company. Through its wholly-owned subsidiary, First Mid Bank, it is engaged in the business of banking. The Company offers trust, farm services, investment services, and retirement planning through its wholly owned subsidiary, it also provides data processing services to affiliates and insurance products and services to customers through its subsidiary. The company's operations cover community banking, wealth management and insurance services. Key revenue is derived from the provision of community banking services.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).